Candel Therapeutics (CADL)
(Delayed Data from NSDQ)
$6.70 USD
+0.19 (2.92%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $6.72 +0.02 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CADL 6.70 +0.19(2.92%)
Will CADL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CADL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CADL
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
Candel (CADL) Reports Upbeat Data From Lung Cancer Study
CADL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409
Other News for CADL
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
7 A-Rated Biotech Stocks Worth Betting on in June
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
Candel Therapeutics to Join Russell 3000? Index